Samir Dalia, MD
Hematology & Oncology · Joplin, MONPI 1235331455
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (33.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by AstraZeneca at 38.4% of the total. Reporting peaked in 2023 at $646 and has fallen 69.0% since, to $200 in 2025.
Across 36 payments — averaging $70.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$982
- Lilly USA, LLC$373
- Novocure GmbH$200
- Covis Pharma GmbH$200
- Johnson & Johnson$195
- Comsort, Inc$100
- plus $504 from 9 others
Across 160 payments — averaging $3033.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$309K
- Alnylam Pharmaceuticals Inc.$53K
- Bristol Myers Squibb$31K
- GSK$28K
- Roche Products Limited$27K
- E.r. Squibb & Sons, L.L.C.$14K
- plus $24K from 4 others
What the payments were for
- Consulting fees$82532%
- Speaking & faculty fees$60023%
- Food & beverage$28411%
- Education$84433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $982 |
| Lilly USA, LLC | 7 | $373 |
| Novocure GmbH | 1 | $200 |
| Covis Pharma GmbH | 1 | $200 |
| Johnson & Johnson(2 entities) | 6 | $195 |
| Comsort, Inc | 1 | $100 |
| AbbVie | 1 | $100 |
| Seagen Inc. | 1 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Tempus AI, Inc | 1 | $75 |
| Pfizer | 5 | $62 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Novocure Inc. | 1 | $25 |
| Foundation Medicine, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,554 in reported general payments places this provider in the 55th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 36 | $625,649 |
| CabometyxCabozantinib S-Malate | 25 | $600,646 |
| ImbruvicaIbrutinib | 34 | $535,978 |
| BrukinsaZanubrutinib | 25 | $346,075 |
| VerzenioAbemaciclib | 14 | $314,718 |
| IbrancePalbociclib | 17 | $270,377 |
| Lenalidomide | 16 | $212,257 |
| XtandiEnzalutamide | 15 | $199,821 |
| KisqaliRibociclib Succinate | 13 | $180,981 |
| ErivedgeVismodegib | 12 | $168,443 |
| ErleadaApalutamide | 11 | $89,995 |
| Abiraterone Acetate | 48 | $79,044 |
| VenclextaVenetoclax | 12 | $51,448 |
| XareltoRivaroxaban | 44 | $46,980 |
| EliquisApixaban | 19 | $22,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $373 | $314,71814 claims |
| PfizerIbrance, Eliquis | $62 | $292,91236 claims |
| Johnson & JohnsonErleada, Xarelto | $195 | $136,97555 claims |
| AbbVieVenclexta | $100 | $51,44812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Joplin
- Anisa HassanJoplin$9K
- Matthew MillerJoplin$8K
- Regine LeconteJoplin$5K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.